Ingen Moves Forward in $40B GSA Schedule for Military and VA Hospitals

YUCAIPA, Calif., July 30, 2009 (GLOBE NEWSWIRE) -- Ingen Technologies, Inc.
(Pink Sheets:IGNT), a leading Medical Device Manufacturer focused in the $8
Billion global Respiratory Markets for the growing ageing population and
emerging markets for Home (DME), Hospital and Aviation Industries, announced
today that the company expects to be listed as a GSA contractor by the end of
the year, and at the same time will finalize the ISO certification in order to
export the new Oxyview Nasal Cannula to China, Japan, Canada and Europe.

Ingen has prepaid the fees required for the Texas based KGMA Business Solutions,
Inc. to finalize the GSA Schedule 65IIA proposal for submission in August-2009.
The GSA Schedule 65IIA allows Ingen to be listed under the U.S. General Services
Administration as a contractor to sell medical products and services to the
military and government owned VA Hospitals. With hundreds of VA Hospitals and
more than 25 million veterans, the new Oxyview Nasal Cannnula will be sold into
all of the respiratory departments at a contract price of $4.50 each. It is
estimated that there are more than 2 million veterans prescribed home oxygen
therapy. The company has already placed the new Oxyview Nasal Cannula with
several VA Hospitals around the country. Projected GSA sales for Ingen are
expected to be $2M annually.

Cheryl Fisher with the Texas based Emergo Group Inc. is scheduled to finalize
ISO training on August 17, 2009. The International Standards Organization (ISO)
required certification with manufacturers who sell products in designated
countries outside the USA. Ingen is a licensed and FDA registered medical device
manufacturer. ISO certification allows Ingen to market and sell the new Oxyview
Nasal Cannula in China, Japan, Australia, Canada and Europe, with projected
sales of $200M annually.

"Ingen will be GSA listed and ISO certified in time to launch the new Oxyview
Nasal Cannula in to new government markets and world markets. This can only
strengthen sales and earnings for our shareholders. The company is now preparing
for a share buy-back program as a part of strengthening the share price. There
are no reverse splits considered now or in the future. The shareholders must be
considered first, and our products and revenues will blaze a new trail for this
company," stated Scott R. Sand, Chief Financial Officer and Chairman of the
Board.

http://www.gsa.gov/Portal/gsa/ep/contentView.do?contentType=GSA_OVERVIEW&content
d=10645

http://www2.va.gov/directory/guide/home.asp?isFlash=1

http://www.emergogroup.com/

http://www.iso.org/iso/home.htm

About Ingen/Oxyview:

Ingen is an established medical device manufacturer with an emerging new medical
product line for the respiratory market worth an estimated $4 Billion in the
U.S., and $8 Billion globally. The company introduced Oxyview into the
respiratory market in late 2007 after securing U.S. and Foreign Patents and
successful licensing with the Food & Drug Administration, and has commenced
domestic and global distribution with manufacture representative organizations,
and OEM partners. In addition to selling its respiratory products within the
global medical industry, the company is selling the same products within other
industries that include aviation, automotive, emergency response, military and
government transportation. The company holds a Device Manufacturing License with
the State of California, Department of Public Health, Food and Drug Branch as it
manufacturers all of its respiratory products in the United States. There are 32
million U.S. patients with Chronic Obstructive Pulmonary Disease (COPD), and 600
million patients worldwide. Ingen Technologies is now the largest manufacturer
of in-line gravity-independent oxygen flow meters.

The Ingen Technologies, Inc. logo is available at
http://www.globenewswire.com/newsroom/prs/?pkgid=2472

Safe Harbor for Forward-Looking Statements: This news release includes
forward-looking statements. While these statements are made to convey to the
public the company's progress, business opportunities and growth prospects,
readers are cautioned that such forward-looking statements represent
management's opinion. Whereas management believes such representations to be
true and accurate based on information and data available to the company at this
time, actual results may differ materially from those described. The company's
operations and business prospects are always subject to risk and uncertainties.
Important factors that may cause actual results to differ are and will be set
forth in the company's periodic filings with the U.S. Securities and Exchange
Commission.

-0-
CONTACT: Ingen Technologies, Inc.
Chris Wirth
909-790-7180
info@ingen-tech.com
www.INGEN-TECH.COM